--- title: "Hong Kong Stock Movement: IMPACT THERAP-B rebounds by 13.74%, can the market sentiment recovery be sustained? Risks of newly listed stocks still need to be vigilant" type: "News" locale: "en" url: "https://longbridge.com/en/news/287321786.md" description: "IMPACT THERAP-B rose 13.74%; CSPC Pharmaceutical Group rose 4.77%, with a transaction volume of HKD 661 million; China Biologic Products fell 0.76%, with a transaction volume of HKD 162 million; Heng Rui Medicine fell 1.36%, with a transaction volume of HKD 156 million; Hansoh Pharmaceutical fell 1.23%, with a market value of HKD 204.2 billion" datetime: "2026-05-22T07:12:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287321786.md) - [en](https://longbridge.com/en/news/287321786.md) - [zh-HK](https://longbridge.com/zh-HK/news/287321786.md) --- # Hong Kong Stock Movement: IMPACT THERAP-B rebounds by 13.74%, can the market sentiment recovery be sustained? Risks of newly listed stocks still need to be vigilant **Hong Kong Stock Movement** IMPACT THERAP-B rose 13.74%. Based on recent key news: 1. On May 21, newly listed stocks in Hong Kong generally fell sharply, with IMPACT THERAP-B dropping over 16%. Market confidence in newly listed stocks was hit, leading to price fluctuations. 2. On May 22, market sentiment warmed up, and the stock price of IMPACT THERAP-B rebounded by 13.74%. Investors reassessed the value of newly listed stocks, driving the price up. 3. No other significant news recently. Newly listed stocks in Hong Kong are experiencing significant volatility, and risks should be monitored. **Stocks with High Trading Volume in the Industry** Stone Pharmaceutical Group rose 4.77%. Based on recent key news: 1. On May 22, Stone Pharmaceutical Group announced that its budesonide enteric-coated capsules received drug registration approval from the National Medical Products Administration. This drug is used to treat adult patients with primary immunoglobulin A nephropathy, enhancing the company's competitiveness in the nephrology field. 2. On May 22, UBS released a report upgrading Stone Pharmaceutical Group's rating from neutral to buy, with a target price of HKD 10.9. UBS pointed out that Stone's leading position in AI drug development has not yet been fully reflected in its valuation, and it is expected that the company's organic revenue will resume growth by 2026. 3. On May 19, Stone Pharmaceutical Group's innovative drug SYH2095 tablets, developed in collaboration with Hangzhou Yingchuang Pharmaceutical Technology, received approval from the National Medical Products Administration to conduct clinical trials in China, further enhancing the company's R&D capabilities. The prospects for AI research and development in the pharmaceutical industry are broad, with significant capital inflow. China Biologic Products Holdings fell 0.76%. Based on recent key news: 1. On May 21, China Biologic Products Holdings and Boehringer Ingelheim jointly promoted the approval of Zongaitini tablets by the National Medical Products Administration for first-line treatment of HER2-mutated non-small cell lung cancer. This approval marks a new era of precision targeted therapy, boosting market confidence in the company's innovative drugs. 2. On May 22, China Biologic Products Holdings announced positive clinical data for its innovative drug M701 at the American Society of Clinical Oncology conference, showing its potential in treating malignant ascites and malignant pleural effusion related to non-small cell lung cancer, further enhancing market recognition of the company's R&D capabilities. 3. On May 19, the company repurchased 1.91 million shares, demonstrating confidence in its own value, which may provide support for the stock price. The pharmaceutical industry's innovative drug development is active, attracting high market attention. Hengrui Medicine fell 1.36%. Based on recent key news: 1. On May 19, Hengrui Medicine's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received notification from the National Medical Products Administration approving the launch of ω-3 triglyceride medium/long-chain fat emulsion/amino acid/glucose injection. This drug is suitable for adult patients with moderate to severe metabolic disorders, providing the energy and nutrients needed for parenteral nutrition therapy. This news had a positive impact on the stock price but could not offset the overall negative market sentiment. 2. On May 20, Goldman Sachs published a research report, stating that Hengrui Medicine's collaboration with multinational pharmaceutical companies will further enhance its global pipeline visibility. Although this news is beneficial for the company's long-term development, it did not significantly boost the stock price in the short term On May 21, the Hong Kong stock market's innovative drug ETF from Invesco has seen continuous net inflows of funds over the past three days, indicating sustained market interest in the innovative drug sector. However, the stock price of HengRui Medicine is still affected by overall market fluctuations. The innovative drug sector shows a high level of prosperity, with significant capital inflows. **Stocks Ranked Among the Top in Industry Market Value** Hansen Pharmaceutical fell by 1.23%. Based on recent key news: 1. On May 22, Hansen Pharmaceutical's HS-10504 tablets were approved by the National Medical Products Administration and included as a breakthrough therapy. This move enhances the company's competitiveness in China's oncology drug market, positively impacting its stock price. Source: Economic Information Daily 2. On May 21, Hansen Pharmaceutical announced that multiple innovative drugs would participate in the medical insurance price reduction and simultaneously launch a charitable drug donation program, covering a large number of low-income patients, enhancing the company's inclusiveness in the market. Source: Jinshi Data 3. On May 21, analysts gave Hansen Pharmaceutical a "Buy" rating with a target price of HKD 47, reflecting market confidence in its innovative drug research and development capabilities. Source: Zhitong Finance The competition in the oncology drug market is intensifying, with clear policy support ### Related Stocks - [07630.HK](https://longbridge.com/en/quote/07630.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) ## Related News & Research - [Don't use AI when emailing Paul Graham](https://longbridge.com/en/news/287659485.md) - [American International College Partners with Sophia Learning to Expand Access to Education for Working Adult Learners](https://longbridge.com/en/news/287625090.md) - [China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says](https://longbridge.com/en/news/287629559.md) - [DeFi Development Corp UK posts wider loss as it pivots to AI agents and digital asset strategy](https://longbridge.com/en/news/287384600.md) - [10:00 ETMeet Clicklinks: The Innovation Hub for Original Drug Discovery](https://longbridge.com/en/news/287433324.md)